CMAS

Across TCGA pan-cancer cohorts, CMAS RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CMAS data layer compared with 6 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CMAS RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CMAS expression acts as an unfavorable survival marker, although some lineages such as LUSC and PRAD show a favorable association.

LUAD, KIRP, and HNSC are the cancer types where CMAS RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.271	0.435	<.001	104	view →
KIRP	DFS	Median	III,IV	0.125	0.700	<.001	65	view →
HNSC	OS	Median	All	0.245	0.498	.006	48	view →
LGG	DFS	Median	All	0.666	0.800	<.001	46	view →
BLCA	DFS	Median	All	0.491	0.689	.004	37	view →
UVM	DFS	Quartile	All	0.261	0.836	<.001	35	view →
BRCA	OS	Median	II,III,IV	0.880	0.942	<.001	30	view →
CESC	DFS	Quartile	All	0.426	0.732	.009	24	view →
UCEC	DFS	Median	All	0.792	0.877	.003	22	view →
LIHC	OS	Median	II,III,IV	0.512	0.692	.014	8	view →
KIRC	DFS	Tertile	IV	0.321	0.550	.024	6	view →
ESCA	DFS	Median	All	0.461	0.593	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CMAS–LUAD (DFS)

Open the LUAD breakdown →